// App-Quantinova.ai

Su1062 : Comparisons of Populations in Faldaprevir Phase III Studies Based on Pegylated Interferon ?-2A and Ribavirin-Predicted Responsiveness and Impact on Achieving Svr12

Researchers

Presenter

  • Donald M. Jensen

Principal Investigators

  • Douglas T. Dieterich

  • Massimo Puoti

  • Edward Tam

  • Jose Luis Calleja

  • Marina Nunez

  • Anne-Marie Quinson

  • Wulf Bocher

  • Florian Voss

  • Joseph Scherer

  • Ira M. Jacobson

  • Manuel Romero-Gomez

  • Graham Foster

  • Tarik Asselah

  • Curtis Cooper

  • Cristina Tural

  • Adrian Streinu-Cercel

  • Stephen D. Ryder

Medical Centers

  • Matei Bals National Institute for Infectious Diseases, Bucharest, Romania

  • New York Presbyterian Weill Cornell Medical Center, New York, NY

  • Medical University of Vienna, Vienna, Austria

  • Gastroenterology and Hepatology Service, Hospital Universitario de Puerta de Hierro-Majadahonda, Universidad Autonoma de Madrid, Madrid, Spain

  • Mount Sinai School of Medicine, New York, NY

  • Azienda Ospedaliera Niguarda Ca Granda, Milano, Italy

  • The University of Chicago Medical Center, Chicago, IL

  • Hopital Beaujon, APHP, University Paris-Diderot and INSERM CRB, Clichy, France

  • Hospital de Valme, Seville, Spain

  • Hospital Universitari Germans Trias I Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain

  • Queen Mary University of London, London, United Kingdom

  • LAIR Centre, Vancouver, BC, Canada

  • Department of Gastroenterology, Queen's Medical Campus, Nottingham, United Kingdom

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Wake Forest University, Winston-Salem, NC

Locations

  • Canada

  • Italy

  • Austria

  • Spain

  • United Kingdom

  • United States

  • France

  • Romania

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Interleukin 28B

  • Interferon

  • Sustained virological response

Drug/Treatment

  • Faldaprevir-sodium

  • Interferon

  • Ribavirin

  • LCB100200

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved